(Q37931969)

25 August 2017

1 reference

title

Agomelatine for the treatment of major depressive disorder (English)

1 reference

25 August 2017

Regina M Carney

1

1 reference

25 August 2017

Richard C Shelton

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

15

1 reference

25 August 2017

page(s)

2411-2419

1 reference

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Prevention of relapse following cognitive therapy vs medications in moderate to severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Melatonin agonists and insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

The circadian basis of winter depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

The persistence of the placebo response in antidepressant clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Agomelatine treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Agomelatine in the treatment of seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Agomelatine: innovative pharmacological approach in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Antidepressant drug effects and depression severity: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Low-dose doxepin: in the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Agomelatine: a preliminary review of a new antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Therapeutic options for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.607812

10.1517/14656566.2011.607812

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference